Dow Jones
39.118,86 -45,24 (-0,12%) Nasdaq
17.732,60 -126,10 (-0,71%) Nikkei 225
39.694,15 +111,07 (+0,28%) EUR/USD
1,0750 +0,0035 (+0,32%) Bitcoin EUR
59.267,15 +2.675,34 (+4,73%) CMC Crypto 200
1.317,32 +33,49 (+2,61%)
GILD Jul 2024 71.000 put
| Chiusura precedente | 1,6400 |
| Aperto | 2,2500 |
| Denaro | 2,3300 |
| Domanda | 3,4000 |
| Prezzo d'esercizio | 71,00 |
| Scadenza | 2024-07-05 |
| Min-Max giorno | 2,2500 - 2,4300 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 382 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
